Safety and Efficacy of a Single Injection of Liposomal Latanoprost in Open-Angle and Angle-Closure Eyes

Background/Objectives: Glaucoma is a leading cause of irreversible global vision loss, with intraocular pressure (IOP) as the sole modifiable risk factor to stall progression. First-line treatment in the form of eye drops suffers from poor bioavailability and low patient adherence, necessitating sustained-release alternatives. This study evaluates the safety and sustained efficacy of a liposomal latanoprost (LipoLat) injection in both open-angle and angle-closure eyes. Methods: This was a 3-month open-label, non-comparative pilot study that included patients aged 40 to 90 with ocular hypertension, primary open- and closed-angle glaucoma. After a 1-month washout from daily topical prostaglandin analogues, participants received a single sub-Tenon’s injection of LipoLat 2 mg/mL. Primary and secondary outcome measures included safety (the incidence of serious adverse events) and IOP-lowering efficacy. Results: Nine of 12 enrolled subjects completed the 3-month follow-up. LipoLat 2 mg/mL was safe, with no serious adverse events reported. There was a significant IOP reduction from a baseline of 23.1 ± 1.76 mmHg to 18.0 ± 1.42 mmHg at month 3 (p < 0.001), representing a maximum 22.6% decrease. Adjusted mixed models confirmed a 5.11 mmHg mean IOP reduction at 3 months, with five subjects showing sustained IOP reduction beyond 3 months, and two subjects remaining medication-free for up to 9 months. Conclusions: In this study, LipoLat is shown to be a safe, well-tolerated treatment for the first time in angle-closure eyes. Its sustained efficacy may also extend beyond 3 months. Larger randomised trials are warranted to further confirm the clinical application in angle-closure eyes.